{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T20:26:48Z","timestamp":1745872008773,"version":"3.28.0"},"reference-count":181,"publisher":"Bentham Science Publishers Ltd.","issue":"16","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Psoriasis is an immune-mediated skin condition affecting people worldwide, presenting at any age, and leading to a substantial burden physically and mentally. The innate and adaptive immune systems interact intricately with the pathomechanisms that underlie disease. T cells can interact with keratinocytes, macrophages, and dendritic cells through the cytokines they secrete. According to recent research, psoriasis flare-ups can cause systemic inflammation and various other co-morbidities, including depression, psoriatic arthritis, and cardio-metabolic syndrome. Additionally, several auto-inflammatory and auto-immune illnesses may be linked to psoriasis. Although psoriasis has no proven treatment, care must strive by treating patients as soon as the disease surfaces, finding and preventing concurrent multimorbidity, recognising and reducing bodily and psychological distress, requiring behavioural modifications, and treating each patient individually. Biomarkers are traits that are assessed at any time along the clinical continuum, from the early stages of a disease through the beginning of treatment (the foundation of precision medicine) to the late stages of treatment (outcomes and endpoints). Systemic therapies that are frequently used to treat psoriasis provide a variety of outcomes. Targeted therapy selection, better patient outcomes, and more cost-effective healthcare would be made possible by biomarkers that reliably predict effectiveness and safety. This review is an attempt to understand the role of Antimicrobial peptides (AMP), Interleukin-38 (IL-38), autophagy 5 (ATG5) protein and squamous cell carcinoma antigen (SCCA) as biomarkers of psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0113894501277656231128060242","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T11:12:48Z","timestamp":1701429168000},"page":"1224-1238","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deciphering the Function of New Therapeutic Targets and Prospective Biomarkers in the Management of Psoriasis"],"prefix":"10.2174","volume":"24","author":[{"given":"Japneet Singh","family":"Purewal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutics, SVKM\u2019s Dr Bhanuben Nanavati College of Pharmacy, V.M. Road, Vile Parle (W), Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav Mahesh","family":"Doshi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutics, SVKM\u2019s Dr Bhanuben Nanavati College of Pharmacy, V.M. Road, Vile Parle (W), Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"109341","DOI":"10.1016\/j.intimp.2022.109341","volume":"113","author":"Parab S","year":"2022","unstructured":"Parab S; Doshi G; An update on emerging immunological targets and their inhibitors in the treatment of psoriasis. Int Immunopharmacol 2022,113((PA)),109341","journal-title":"Int Immunopharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"Damiani G.","year":"2021","unstructured":"Damiani G.; Bragazzi N.L.; Karimkhani Aksut C.; Wu D.; Alicandro G.; McGonagle D.; Guo C.; Dellavalle R.; Grada A.; Wong P.; La Vecchia C.; Tam L.S.; Cooper K.D.; Naghavi M.; The global, regional, and national burden of psoriasis: Results and insights from the global burden of disease 2019 Study. Front Med 2021,8,743180","journal-title":"Front Med"},{"key":"ref=3","unstructured":"Global report on psoriasis Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/204417 (Cited 2023 Jun 13)."},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.3390\/jcm10153199","volume":"10","author":"Honma M.","year":"2021","unstructured":"Honma M.; Nozaki H.; Molecular pathogenesis of psoriasis and biomarkers reflecting disease activity. J Clin Med 2021,10(15),3199","journal-title":"J Clin Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"479354","DOI":"10.1155\/2015\/479354","volume":"2015","author":"Napolitano M","year":"2015","unstructured":"Napolitano M; Megna M; Monfrecola G.; Insulin resistance and skin diseases. Sci World J 2015,2015,479354","journal-title":"Sci World J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"Frank Nestle P.O.","year":"2009","unstructured":"Frank Nestle P.O.; Kaplan D.H.; Barker J.; Psoriasis. N Engl J Med 2009,361(5),496-509","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"Lowes M.A.","year":"2014","unstructured":"Lowes M.A.; Su\u00e1rez-Fari\u00f1as M.; Krueger J.G.; Immunology of psoriasis. Annu Rev Immunol 2014,32(1),227-255","journal-title":"Annu Rev Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/1346-8138.15840","volume":"48","author":"Yamazaki F.","year":"2021","unstructured":"Yamazaki F.; Psoriasis: Comorbidities. J Dermatol 2021,48(6),732-740","journal-title":"J Dermatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"Korman N.J.","year":"2020","unstructured":"Korman N.J.; Management of psoriasis as a systemic disease: What is the evidence? Br J Dermatol 2020,182(4),840-848","journal-title":"Br J Dermatol"},{"key":"ref=10","first-page":"278","volume":"63","author":"Kim W.B.","year":"2017","unstructured":"Kim W.B.; Jerome D.; Yeung J.; Diagnosis and management of psoriasis. Can Fam Physician 2017,63(4),278-285","journal-title":"Can Fam Physician"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"Parisi R.","year":"2013","unstructured":"Parisi R.; Symmons D.P.M.; Griffiths C.E.M.; Ashcroft D.M.; Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 2013,133(2),377-385","journal-title":"J Invest Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.3390\/ijms22094983","volume":"22","author":"Petit R.G.","year":"2021","unstructured":"Petit R.G.; Cano A.; Ortiz A.; Espina M.; Prat J.; Mu\u00f1oz M.; Severino P.; Souto E.B.; Garc\u00eda M.L.; Pujol M.; S\u00e1nchez-L\u00f3pez E.; Psoriasis: From pathogenesis to pharmacological and nano-technological-based therapeutics. Int J Mol Sci 2021,22(9),4983","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.3390\/ijms20184347","volume":"20","author":"Kamiya K.","year":"2019","unstructured":"Kamiya K.; Kishimoto M.; Sugai J.; Komine M.; Ohtsuki M.; Risk factors for the development of psoriasis. Int J Mol Sci 2019,20(18),4347","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2340\/00015555-3384","volume":"100","author":"Dand N.","year":"2020","unstructured":"Dand N.; Mahil S.; Capon F.; Smith C.; Simpson M.; Barker J.; Psoriasis and genetics. Acta Derm Venereol 2020,100(3),55-65","journal-title":"Acta Derm Venereol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","volume":"99","author":"Ogawa K.","year":"2020","unstructured":"Ogawa K.; Okada Y.; The current landscape of psoriasis genetics in 2020. J Dermatol Sci 2020,99(1),2-8","journal-title":"J Dermatol Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jid.2016.11.007","volume":"137","author":"Hwang S.T.","year":"2017","unstructured":"Hwang S.T.; Nijsten T.; Elder J.T.; Recent highlights in psoriasis research. J Invest Dermatol 2017,137(3),550-556","journal-title":"J Invest Dermatol"},{"key":"ref=17","first-page":"278","volume":"63","author":"Tveit K.S.","year":"2019","unstructured":"Tveit K.S.; Effect of herring roe lipids on mild psoriasis. Nordic Cong Dermatol Venereol 2019,63(April),278-285","journal-title":"Nordic Cong Dermatol Venereol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.gpb.2015.04.002","volume":"13","author":"Jiang S.","year":"2015","unstructured":"Jiang S.; Hinchliffe T.E.; Wu T.; Biomarkers of an autoimmune skin disease-psoriasis. Genomics Proteom Bioinform 2015,13(4),224-233","journal-title":"Genomics Proteom Bioinform"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/neuonc\/nox242","volume":"20","author":"Cagney D.N.","year":"2018","unstructured":"Cagney D.N.; Sul J.; Huang R.Y.; Ligon K.L.; Wen P.Y.; Alexander B.M.; The FDA NIH biomarkers, endpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-oncol 2018,20(9),1162-1172","journal-title":"Neuro-oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"Langley R.G.B.","year":"2005","unstructured":"Langley R.G.B.; Krueger G.G.; Griffiths C.E.M.; Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005,64(Suppl 2),ii18-ii23","journal-title":"Ann Rheum Dis"},{"key":"ref=21","first-page":"119","volume":"94","author":"Chung H.J.","year":"2014","unstructured":"Chung H.J.; Marley-Kemp D.; Keller M.; St C.; Rupioid psoriasis and other skin diseases with rupioid manifestations. Cutis 2014,94(3),119-121","journal-title":"Cutis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09546630802032611","volume":"19","author":"Feldman S.R.","year":"2008","unstructured":"Feldman S.R.; Brown K.L.; Heald P.; \u2018Coral reef\u2019 psoriasis: A marker of resistance to topical treatment. J Dermatolog Treat 2008,19(5),257-258","journal-title":"J Dermatolog Treat"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/823469","volume":"2013","author":"Gul Mert G.","year":"2013","unstructured":"Gul Mert G.; Incecik F.; Gunasti S.; Herguner O.; Altunbasak S.; Psoriasiform drug eruption associated with sodium valproate. Case Rep Pediatr 2013,2013,1-3","journal-title":"Case Rep Pediatr"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"E1407","DOI":"10.1503\/cmaj.200517","volume":"192","author":"G\u00f3mez-Arias P.J.","year":"2020","unstructured":"G\u00f3mez-Arias P.J.; Garc\u00eda-Nieto A.J.V.; Rupioid psoriasis on the hands. CMAJ 2020,192(45),E1407","journal-title":"CMAJ"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2147\/CCID.S408245","volume":"16","author":"Yang Y.","year":"2023","unstructured":"Yang Y.; Lyu X.; Lithium-associated generalized ostraceous psoriasis treated with adalimumab: A case report. Clin Cosmet Investig Dermatol 2023,16,947-950","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/PTT.S285832","volume":"10","author":"Rowawi R.","year":"2020","unstructured":"Rowawi R.; Dwipangestu G.; Suwarsa O.; Dharmadji H.P.; Sutedja E.; Pangastuti M.; Gunawan H.; A successful treatment of ostraceous psoriasis associated with psoriatic arthritis in children: A case report. Psoriasis 2020,10,61-66","journal-title":"Psoriasis"},{"key":"ref=27","first-page":"512","volume":"63","author":"Park M.","year":"2018","unstructured":"Park M.; Park M.J.; Choi M.S.; Nam C.H.; Park B.C.; Hong S.P.; Kim M.H.; A case of ostraceous psoriasis with psoriatic arthritis in an AIDS patient. Indian J Dermatol 2018,63(6),512-514","journal-title":"Indian J Dermatol"},{"key":"ref=28","first-page":"560","volume":"19","author":"Badri T.","year":"2023","unstructured":"Badri T.; Kumar P.; Oakley A.M.; Plaque psoriasis. Pract Nurs 2023,19(11),560-565","journal-title":"Pract Nurs"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e29536","DOI":"10.7759\/cureus.29536","volume":"14","author":"Dhabale A.","year":"2022","unstructured":"Dhabale A.; Nagpure S.; Types of psoriasis and their effects on the immune system. Cureus 2022,14(9),e29536","journal-title":"Cureus"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/CCID.S189000","volume":"12","author":"Micali G.","year":"2020","unstructured":"Micali G.; Verz\u00ec A.E.; Giuffrida G.; Panebianco E.; Musumeci M.L.; Lacarrubba F.; Inverse psoriasis: From diagnosis to current treatment options. Clin Cosmet Investig Dermatol 2020,12,953-959","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s13555-021-00536-6","volume":"11","author":"Hong J.J.","year":"2021","unstructured":"Hong J.J.; Mosca M.L.; Hadeler E.K.; Brownstone N.D.; Bhutani T.; Liao W.J.; Genital and inverse\/intertriginous psoriasis: An updated review of therapies and recommendations for practical management. Dermatol Ther 2021,11(3),833-844","journal-title":"Dermatol Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"Dopytalska K.","year":"2018","unstructured":"Dopytalska K.; Sobolewski P.; B\u0142aszczak A.; Szyma\u0144ska E.; Walecka I.; Psoriasis in special localizations. Reumatologia 2018,56(6),392-398","journal-title":"Reumatologia"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"CD001213","DOI":"10.1002\/14651858.CD001213.pub2","volume":"4","author":"Chalmers R","year":"2019","unstructured":"Chalmers R; O\u2019sullivan T; Owen CM; Griffiths CEM; Interventions for guttate psoriasis. Cochrane Database Syst Rev 2019,4,CD001213","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=34","author":"Saleh D.","year":"2022","unstructured":"Saleh D.; Tanner L.S.; Guttate Psoriasis 2022","journal-title":"Guttate Psoriasis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"Rendon A.","year":"2019","unstructured":"Rendon A.; Sch\u00e4kel K.; Psoriasis pathogenesis and treatment. Int J Mol Sci 2019,20(6),1475","journal-title":"Int J Mol Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","volume":"18","author":"Uppala R.","year":"2021","unstructured":"Uppala R.; Tsoi L.C.; Harms P.W.; Wang B.; Billi A.C.; Maverakis E.; Michelle Kahlenberg J.; Ward N.L.; Gudjonsson J.E.; \u201cAutoinflammatory psoriasis\u201d-genetics and biology of pustular psoriasis. Cell Mol Immunol 2021,18(2),307-317","journal-title":"Cell Mol Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/PTT.S288345","volume":"11","author":"Lo Y.","year":"2021","unstructured":"Lo Y.; Tsai T.F.; Updates on the treatment of erythrodermic psoriasis. Psoriasis 2021,11,59-73","journal-title":"Psoriasis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40259-015-0119-4","volume":"29","author":"Stinco G.","year":"2015","unstructured":"Stinco G.; Errichetti E.; Erythrodermic psoriasis: Current and future role of biologicals. BioDrugs 2015,29(2),91-101","journal-title":"BioDrugs"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.25259\/IJDVL_22_2021","volume":"88","author":"Neema S.","year":"2021","unstructured":"Neema S.; Sandhu S.; Gupta A.; Jagadeesan S.; Vasudevan B.; Unconventional treatment options in psoriasis: A review. Indian J Dermatol Venereol Leprol 2021,88(2),137-143","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejpb.2022.05.012","volume":"176","author":"Mascarenhas-Melo F.","year":"2022","unstructured":"Mascarenhas-Melo F.; Carvalho A.; Gon\u00e7alves M.B.S.; Paiva-Santos A.C.; Veiga F.; Nanocarriers for the topical treatment of psoriasis - pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology. Eur J Pharm Biopharm 2022,176,95-107","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","volume":"21","author":"Tokuyama M.","year":"2020","unstructured":"Tokuyama M.; Mabuchi T.; New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci 2020,21(20),7488","journal-title":"Int J Mol Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","volume":"61","author":"Menter A.","year":"2009","unstructured":"Menter A.; Korman N.J.; Elmets C.A.; Feldman S.R.; Gelfand J.M.; Gordon K.B.; Gottlieb A.B.; Koo J.Y.M.; Lebwohl M.; Lim H.W.; Van Voorhees A.S.; Beutner K.R.; Bhushan R.; Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2009,61(3),451-485","journal-title":"J Am Acad Dermatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.abd.2021.03.001","volume":"96","author":"Barros N.M.","year":"2021","unstructured":"Barros N.M.; Sbroglio L.L.; Buffara M.O.; Baka J.L.C.S.; Pessoa A.S.; Azulay-Abulafia L.; Phototherapy. An Bras Dermatol 2021,96(4),397-407","journal-title":"An Bras Dermatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10103-017-2360-1","volume":"33","author":"Zhang P.","year":"2018","unstructured":"Zhang P.; Wu M.X.; A clinical review of phototherapy for psoriasis. Lasers Med Sci 2018,33(1),173-180","journal-title":"Lasers Med Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5070\/D39R12N60X","volume":"16","author":"Nolan B.V.","year":"2010","unstructured":"Nolan B.V.; Yentzer B.A.; Feldman S.R.; A review of home phototherapy for psoriasis. Dermatol Online J 2010,16(2),1","journal-title":"Dermatol Online J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","volume":"81","author":"Michielsens C.A.J.","year":"2021","unstructured":"Michielsens C.A.J.; van Muijen M.E.; Verhoef L.M.; van den Reek J.M.P.A.; de Jong E.M.G.J.; Dose tapering of biologics in patients with psoriasis: A scoping review. Drugs 2021,81(3),349-366","journal-title":"Drugs"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/genes12091398","volume":"12","author":"Caputo V.","year":"2021","unstructured":"Caputo V.; Strafella C.; Cosio T.; Lanna C.; Campione E.; Novelli G.; Giardina E.; Cascella R.; Pharmacogenomics: An update on biologics and small-molecule drugs in the treatment of psoriasis. Genes 2021,12(9),1398","journal-title":"Genes"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"Kamata M.","year":"2020","unstructured":"Kamata M.; Tada Y.; Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: A literature review. Int J Mol Sci 2020,21(5),1690","journal-title":"Int J Mol Sci"},{"key":"ref=49","first-page":"97","volume":"93","author":"Gr\u00e4n F.","year":"2020","unstructured":"Gr\u00e4n F.; Kerstan A.; Serfling E.; Goebeler M.; Muhammad K.; Current developments in the immunology of psoriasis. Yale J Biol Med 2020,93(1),97-110","journal-title":"Yale J Biol Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40272-021-00476-w","volume":"23","author":"Blair H.A.","year":"2021","unstructured":"Blair H.A.; Secukinumab: A review in moderate to severe pediatric plaque psoriasis. Paediatr Drugs 2021,23(6),601-608","journal-title":"Paediatr Drugs"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","volume":"15","author":"Ruggiero A.","year":"2022","unstructured":"Ruggiero A.; Picone V.; Martora F.; Fabbrocini G.; Megna M.; Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: A review of the real-world evidence. Clin Cosmet Investig Dermatol 2022,15,1649-1658","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Jiang Y.","year":"2023","unstructured":"Jiang Y.; Chen Y.; Yu Q.; Shi Y.; Biologic and small-molecule therapies for moderate-to-severe psoriasis: Focus on psoriasis comorbidities. BioDrugs 2023,37(1),35-55","journal-title":"BioDrugs"},{"key":"ref=53","unstructured":"Focus Area: Biomarkers | FDA Available from: https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/focus-area-biomarkers (Cited 2023 Jul 23)."},{"key":"ref=54","unstructured":"Biomarkers Available from: https:\/\/www.niehs.nih.gov\/health\/topics\/science\/biomarkers\/index.cfm (Cited 2023 Jul 22)."},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3343\/alm.2023.43.3.221","volume":"43","author":"Yun Y.M.","year":"2023","unstructured":"Yun Y.M.; Apolipoprotein B.; Apolipoprotein B, Non-HDL cholesterol, and ldl cholesterol as markers for atherosclerotic cardiovascular disease risk assessment. Ann Lab Med 2023,43(3),221-222","journal-title":"Ann Lab Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e31909","DOI":"10.1097\/MD.0000000000031909","volume":"101","author":"Ahn C.","year":"2022","unstructured":"Ahn C.; Kang C.; Ahn H.J.; You Y.; Park J.S.; Min J.H.; Jeong W.; Cho Y.; Ryu S.; In Y.N.; Serum total cholesterol level as a potential predictive biomarker for neurological outcomes in cardiac arrest survivors who underwent target temperature management. Medicine 2022,101(46),e31909","journal-title":"Medicine"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"Califf R.M.","year":"2018","unstructured":"Califf R.M.; Biomarker definitions and their applications. Exp Biol Med 2018,243(3),213-221","journal-title":"Exp Biol Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.33549\/physiolres.934398","volume":"69","author":"Kunc P.","year":"2020","unstructured":"Kunc P.; Fabry J.; Lucanska M.; Pecova R.; Biomarkers of bronchial asthma. Physiol Res 2020,69(Suppl. 1),S29-S34","journal-title":"Physiol Res"},{"key":"ref=59","unstructured":"About Biomarkers and Qualification | FDA Available from: https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/about-biomarkers-and-qualification (Cited 2023 Jul 23)."},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjd.21627","volume":"187","author":"Ramessur R.","year":"2022","unstructured":"Ramessur R.; Corbett M.; Marshall D.; Acencio M.L.; Barbosa I.A.; Dand N.; Di Meglio P.; Haddad S.; Jensen A.H.M.; Koopmann W.; Mahil S.K.; Ostaszewski M.; Rahmatulla S.; Rastrick J.; Saklatvala J.; Weidinger S.; Wright K.; Eyerich K.; Ndlovu M.; Barker J.N.; Skov L.; Conrad C.; Smith C.H.; Biomarkers of disease progression in people with psoriasis: A scoping review. Br J Dermatol 2022,187(4),481-493","journal-title":"Br J Dermatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.3390\/ijms222111401","volume":"22","author":"Luo Y.","year":"2021","unstructured":"Luo Y.; Song Y.; Mechanism of antimicrobial peptides: antimicrobial, anti-inflammatory and antibiofilm activities. Int J Mol Sci 2021,22(21),11401","journal-title":"Int J Mol Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"D933","DOI":"10.1093\/nar\/gkn823","volume":"37","author":"Wang G.","year":"2009","unstructured":"Wang G.; Li X.; Wang Z.; APD2: The updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 2009,37(Database issue),D933-D937","journal-title":"Nucleic Acids Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fonc.2015.00144","volume":"5","author":"Kuroda K.","year":"2015","unstructured":"Kuroda K.; Okumura K.; Isogai H.; Isogai E.; The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol 2015,5(JUN),144","journal-title":"Front Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.3390\/jcm11175074","volume":"11","author":"Agakidou E.","year":"2022","unstructured":"Agakidou E.; Agakidis C.; Kontou A.; Chotas W.; Sarafidis K.; Antimicrobial peptides in early-life host defense, perinatal infections, and necrotizing enterocolitis-an update. J Clin Med 2022,11(17),5074","journal-title":"J Clin Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/18755305MTAwENDE80","volume":"27","author":"Kaur-Boparai J.","year":"2020","unstructured":"Kaur-Boparai J.; Sharma P.K.; Mini review on antimicrobial peptides, sources, mechanism and recent applications. Protein Pept Lett 2020,27(1),4-16","journal-title":"Protein Pept Lett"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.3390\/molecules27123703","volume":"27","author":"Bakare O.O.","year":"2022","unstructured":"Bakare O.O.; Gokul A.; Fadaka A.O.; Wu R.; Niekerk L.A.; Barker A.M.; Keyster M.; Klein A.; Plant Antimicrobial Peptides (PAMPs): Features, applications, production, expression, and challenges. Molecules 2022,27(12),3703","journal-title":"Molecules"},{"key":"ref=67","first-page":"1695","volume":"371","author":"Destoumieux-Garz\u00f3n D","year":"1695","unstructured":"Destoumieux-Garz\u00f3n D; Rosa RD; Schmitt P; Barreto C; Vidal-Dupiol J; Mitta G; Antimicrobial peptides in marine invertebrate health and disease. Phil Transac Royal Soc B: Biol Sci 1695,371,1695","journal-title":"Phil Transac Royal Soc B: Biol Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/biom8010004","volume":"8","author":"Kumar P.","year":"2018","unstructured":"Kumar P.; Kizhakkedathu J.; Straus S.; Antimicrobial peptides: Diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. Biomolecules 2018,8(1),4","journal-title":"Biomolecules"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3892\/etm.2022.11124","volume":"23","author":"Branisteanu D.","year":"2022","unstructured":"Branisteanu D.; Cojocaru C.; Diaconu R.; Porumb E.; Alexa A.; Nicolescu A.; Brihan I.; Bogdanici C.; Branisteanu G.; Dimitriu A.; Zemba M.; Anton N.; Toader M.; Grechin A.; Branisteanu D.; Update on the etiopathogenesis of psoriasis (Review). Exp Ther Med 2022,23(3),201","journal-title":"Exp Ther Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.clindermatol.2007.08.016","volume":"25","author":"B\u00fcchau A.S.","year":"2007","unstructured":"B\u00fcchau A.S.; Gallo R.L.; Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 2007,25(6),616-624","journal-title":"Clin Dermatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"11691","DOI":"10.3390\/ijms222111691","volume":"22","author":"Bin Hafeez A.","year":"2021","unstructured":"Bin Hafeez A.; Jiang X.; Bergen P.J.; Zhu Y.; Antimicrobial peptides: An update on classifications and databases. Int J Mol Sci 2021,22(21),11691","journal-title":"Int J Mol Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1189\/jlb.0704409","volume":"77","author":"Harder J.","year":"2005","unstructured":"Harder J.; Schr\u00f6der J.M.; Psoriatic scales: A promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 2005,77(4),476-486","journal-title":"J Leukoc Biol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00018-011-0715-5","volume":"68","author":"Penberthy W.T.","year":"2011","unstructured":"Penberthy W.T.; Chari S.; Cole A.L.; Cole A.M.; Retrocyclins and their activity against HIV-1. Cell Mol Life Sci 2011,68(13),2231-2242","journal-title":"Cell Mol Life Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/v13071246","volume":"13","author":"Xu C.","year":"2021","unstructured":"Xu C.; Wang A.; Marin M.; Honnen W.; Ramasamy S.; Porter E.; Subbian S.; Pinter A.; Melikyan G.B.; Lu W.; Chang T.L.; Human defensins inhibit SARS-CoV-2 infection by blocking viral entry. Viruses 2021,13(7),1246","journal-title":"Viruses"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1016\/j.jmb.2013.09.038","volume":"425","author":"Wilson S.S.","year":"2013","unstructured":"Wilson S.S.; Wiens M.E.; Smith J.G.; Antiviral mechanisms of human defensins. J Mol Biol 2013,425(24),4965-4980","journal-title":"J Mol Biol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.3390\/ijms21186791","volume":"21","author":"Takahashi T.","year":"2020","unstructured":"Takahashi T.; Yamasaki K.; Psoriasis and antimicrobial peptides. Int J Mol Sci 2020,21(18),6791","journal-title":"Int J Mol Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/humupd\/dmac032","volume":"29","author":"Zhai Y.J.","year":"2023","unstructured":"Zhai Y.J.; Feng Y.; Ma X.; Ma F.; Defensins: Defenders of human reproductive health. Hum Reprod Update 2023,29(1),126-154","journal-title":"Hum Reprod Update"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1515\/hsz-2017-0106","volume":"398","author":"Kudryashova E.","year":"2017","unstructured":"Kudryashova E.; Seveau S.M.; Kudryashov D.S.; Targeting and inactivation of bacterial toxins by human defensins. Biol Chem 2017,398(10),1069-1085","journal-title":"Biol Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1159\/000490183","volume":"47","author":"Chen X.","year":"2018","unstructured":"Chen X.; Zou X.; Qi G.; Tang Y.; Guo Y.; Si J.; Liang L.; Roles and mechanisms of human cathelicidin LL-37 in cancer. Cell Physiol Biochem 2018,47(3),1060-1073","journal-title":"Cell Physiol Biochem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1151926","DOI":"10.3389\/fimmu.2023.1151926","volume":"14","author":"Zhang Q.","year":"2023","unstructured":"Zhang Q.; Ul Ain Q.; Schulz C.; Pircher J.; Role of antimicrobial peptide cathelicidin in thrombosis and thromboinflammation. Front Immunol 2023,14,1151926","journal-title":"Front Immunol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"880961","DOI":"10.3389\/fimmu.2022.880961","volume":"13","author":"Aloul K.M.","year":"2022","unstructured":"Aloul K.M.; Nielsen J.E.; Defensor E.B.; Lin J.S.; Fortkort J.A.; Shamloo M.; Cirillo J.D.; Gombart A.F.; Barron A.E.; Upregulating human cathelicidin antimicrobial peptide LL-37 expression may prevent severe COVID-19 inflammatory responses and reduce microthrombosis. Front Immunol 2022,13,880961","journal-title":"Front Immunol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1128\/IAI.06224-11","volume":"80","author":"Schrumpf J.A.","year":"2012","unstructured":"Schrumpf J.A.; van Sterkenburg M.A.J.A.; Verhoosel R.M.; Zuyderduyn S.; Hiemstra P.S.; Interleukin 13 exposure enhances vitamin D-mediated expression of the human cathelicidin antimicrobial peptide 18\/LL-37 in bronchial epithelial cells. Infect Immun 2012,80(12),4485-4494","journal-title":"Infect Immun"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1126\/science.1260972","volume":"347","author":"Zhang L.","year":"2015","unstructured":"Zhang L.; Guerrero-Juarez C.F.; Hata T.; Bapat S.P.; Ramos R.; Plikus M.V.; Gallo R.L.; Dermal adipocytes protect against invasive Staphylococcus aureus skin infection. Science 2015,347(6217),67-71","journal-title":"Science"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1084\/jem.192.7.1069","volume":"192","author":"Yang D.","year":"2000","unstructured":"Yang D.; Chen Q.; Schmidt A.P.; Anderson G.M.; Wang J.M.; Wooters J.; Oppenheim J.J.; Chertov O.; LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000,192(7),1069-1074","journal-title":"J Exp Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1189\/jlb.4A1113-604RR","volume":"96","author":"Tripathi S.","year":"2014","unstructured":"Tripathi S.; Verma A.; Kim E.J.; White M.R.; Hartshorn K.L.; LL-37 modulates human neutrophil responses to influenza A virus. J Leukoc Biol 2014,96(5),931-938","journal-title":"J Leukoc Biol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.7150\/ijbs.41940","volume":"16","author":"Zeng J.","year":"2020","unstructured":"Zeng J.; Lei L.; Zeng Q.; Yao Y.; Wu Y.; Li Q.; Gao L.; Du H.; Xie Y.; Huang J.; Tan W.; Lu J.; Ozone therapy attenuates NF-\u03baB-mediated local inflammatory response and activation of TH17 cells in treatment for psoriasis. Int J Biol Sci 2020,16(11),1833-1845","journal-title":"Int J Biol Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"118677","DOI":"10.1016\/j.bbamcr.2020.118677","volume":"1867","author":"Gonzalez L.L.","year":"2020","unstructured":"Gonzalez L.L.; Garrie K.; Turner M.D.; Role of S100 proteins in health and disease. Biochim Biophys Acta Mol Cell Res 2020,1867(6),118677","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.0022-202X.2004.22719.x","volume":"123","author":"Eckert R.L.","year":"2004","unstructured":"Eckert R.L.; Broome A.M.; Ruse M.; Robinson N.; Ryan D.; Lee K.; S100 proteins in the epidermis. J Invest Dermatol 2004,123(1),23-33","journal-title":"J Invest Dermatol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1191645","DOI":"10.3389\/fimmu.2023.1191645","volume":"14","author":"Liang H.","year":"2023","unstructured":"Liang H.; Li J.; Zhang K.; Pathogenic role of S100 proteins in psoriasis. Front Immunol 2023,14,1191645","journal-title":"Front Immunol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/002215540305100513","volume":"51","author":"Broome A.M.","year":"2003","unstructured":"Broome A.M.; Ryan D.; Eckert R.L.; S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem 2003,51(5),675-685","journal-title":"J Histochem Cytochem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/01.ASW.0000533722.06780.03","volume":"31","author":"Lallyett C.","year":"2018","unstructured":"Lallyett C.; Yeung C.Y.C.; Nielson R.H.; Zeef L.A.H.; Chapman-Jones D.; Kjaer M.; Kadler K.E.; Changes in S100 proteins identified in healthy skin following electrical stimulation: relevance for wound healing. Adv Skin Wound Care 2018,31(7),322-327","journal-title":"Adv Skin Wound Care"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/728052","volume":"2010","author":"Zimmer D.B.","year":"2010","unstructured":"Zimmer D.B.; Weber D.J.; The calcium-dependent interaction of s100b with its protein targets. Cardiovasc Psychiatry Neurol 2010,2010,1-17","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.3390\/molecules27196640","volume":"27","author":"Kurpet K.","year":"2022","unstructured":"Kurpet K.; Chwatko G.; S100 proteins as novel therapeutic targets in psoriasis and other autoimmune diseases. Molecules 2022,27(19),6640","journal-title":"Molecules"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"758004","DOI":"10.3389\/fimmu.2021.758004","volume":"12","author":"Chen Y.","year":"2021","unstructured":"Chen Y.; Wang C.; Song J.; Xu R.; Ruze R.; Zhao Y.; S100A2 is a prognostic biomarker involved in immune infiltration and predict immunotherapy response in pancreatic cancer. Front Immunol 2021,12,758004","journal-title":"Front Immunol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1158\/0008-5472.CAN-17-1294","volume":"77","author":"Chow K.H.","year":"2017","unstructured":"Chow K.H.; Park H.J.; George J.; Yamamoto K.; Gallup A.D.; Graber J.H.; Chen Y.; Jiang W.; Steindler D.A.; Neilson e.g.; Kim B.Y.S.; Yun K.; S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Res 2017,77(19),5360-5373","journal-title":"Cancer Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13075-017-1444-4","volume":"19","author":"Turnier J.L.","year":"2017","unstructured":"Turnier J.L.; Fall N.; Thornton S.; Witte D.; Bennett M.R.; Appenzeller S.; Klein-Gitelman M.S.; Grom A.A.; Brunner H.I.; Urine S100 proteins as potential biomarkers of lupus nephritis activity. Arthritis Res Ther 2017,19(1),242","journal-title":"Arthritis Res Ther"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.21037\/atm-21-1101","volume":"9","author":"Qian L.","year":"2021","unstructured":"Qian L.; Gong J.; Ma W.; Sun Y.; Hong J.; Xu D.; Chu M.; Circulating S100A4 as a prognostic biomarker for patients with nonparoxysmal atrial fibrillation after catheter ablation. Ann Transl Med 2021,9(18),1400-1400","journal-title":"Ann Transl Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1186\/s40169-016-0120-7","volume":"5","author":"Loosen S.H.","year":"2016","unstructured":"Loosen S.H.; Benz F.; Niedeggen J.; Schmeding M.; Sch\u00fcller F.; Koch A.; Vucur M.; Tacke F.; Trautwein C.; Roderburg C.; Neumann U.P.; Luedde T.; Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma. Clin Transl Med 2016,5(1),e39","journal-title":"Clin Transl Med"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.1177\/1010428318767195","volume":"40","author":"Onsurathum S.","year":"2018","unstructured":"Onsurathum S.; Haonon O.; Pinlaor P.; Pairojkul C.; Khuntikeo N.; Thanan R.; Roytrakul S.; Pinlaor S.; Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma. Tumour Biol 2018,40(4)","journal-title":"Tumour Biol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8465083","volume":"2020","author":"Borsky P.","year":"2020","unstructured":"Borsky P.; Fiala Z.; Andrys C.; Beranek M.; Hamakova K.; Malkova A.; Svadlakova T.; Krejsek J.; Palicka V.; Borska L.; Rehacek V.; Alarmins HMGB1, IL-33, S100A7, and S100A12 in psoriasis vulgaris. Mediat Inflamm 2020,2020(7),1-7","journal-title":"Mediat Inflamm"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1002\/ctm2.459","volume":"11","author":"Lu Z.","year":"2021","unstructured":"Lu Z.; Zheng S.; Liu C.; Wang X.; Zhang G.; Wang F.; Wang S.; Huang J.; Mao S.; Lei Y.; Wang Z.; Sun N.; He J.; S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. Clin Transl Med 2021,11(7),e459","journal-title":"Clin Transl Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12935-016-0316-3","volume":"16","author":"Liu G.","year":"2016","unstructured":"Liu G.; Wu Q.; Liu G.; Song X.; Zhang J.; Retraction Note: Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans. Cancer Cell Int 2016,16(1),40","journal-title":"Cancer Cell Int"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e4183","DOI":"10.1371\/journal.pone.0004183","volume":"4","author":"Qin W.","year":"2009","unstructured":"Qin W.; Ho L.; Wang J.; Peskind E.; Pasinetti G.M.; S100A7, a novel Alzheimer\u2019s disease biomarker with non-amyloidogenic \u03b1-secretase activity acts via selective promotion of ADAM-10. PLoS One 2009,4(1),e4183","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"e0213344","DOI":"10.1371\/journal.pone.0213344","volume":"14","author":"Duvetorp A.","year":"2019","unstructured":"Duvetorp A.; S\u00f6derman J.; Assarsson M.; Skarstedt M.; Svensson \u00c5.; Seifert O.; Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8\/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8\/A9 protein levels in serum. PLoS One 2019,14(3),e0213344","journal-title":"PLoS One"},{"key":"ref=105","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/696415","volume":"2014","author":"Hansson C","year":"2014","unstructured":"Hansson C; Eriksson C; Alenius GM; S-Calprotectin (S100A8\/S100A9): A potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res 2014,2014","journal-title":"J Immunol Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","volume":"22","author":"Jarlborg M.","year":"2020","unstructured":"Jarlborg M.; Courvoisier D.S.; Lamacchia C.; Martinez Prat L.; Mahler M.; Bentow C.; Finckh A.; Gabay C.; Nissen M.J.; Serum calprotectin: A promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther 2020,22(1),105","journal-title":"Arthritis Res Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"810338","DOI":"10.3389\/fimmu.2022.810338","volume":"13","author":"Li Y.","year":"2022","unstructured":"Li Y.; He Y.; Chen S.; Wang Q.; Yang Y.; Shen D.; Ma J.; Wen Z.; Ning S.; Chen H.; S100A12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis. Front Immunol 2022,13,810338","journal-title":"Front Immunol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"2633123","DOI":"10.1155\/2022\/2633123","volume":"2022","author":"Xie J","year":"2022","unstructured":"Xie J; Luo C; Mo B; Inflammation and oxidative stress role of s100a12 as a potential diagnostic and therapeutic biomarker in acute myocardial infarction. Oxid Med Cell Longev 2022,2022,2633123","journal-title":"Oxid Med Cell Longev"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/s41598-020-58534-1","volume":"10","author":"Wang X.","year":"2020","unstructured":"Wang X.; Sun Z.; Tian W.; Piao C.; Xie X.; Zang J.; Peng S.; Yu X.; Wang Y.; S100A12 is a promising biomarker in papillary thyroid cancer. Sci Rep 2020,10(1),1724","journal-title":"Sci Rep"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jped.2023.03.002","volume":"99","author":"Witarto B.S.","year":"2023","unstructured":"Witarto B.S.; Visuddho V.; Witarto A.P.; Sampurna M.T.A.; Irzaldy A.; Performance of fecal S100A12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: A systematic review and meta-analysis. J Pediatr 2023,99(5),432-442","journal-title":"J Pediatr"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.3390\/jcm10225320","volume":"10","author":"Batycka-Baran A.","year":"2021","unstructured":"Batycka-Baran A.; Matusiak \u0141.; Nowicka-Suszko D.; Szepietowski J.C.; Baran W.; Increased serum levels of S100A4 and S100A15 in individuals suffering from hidradenitis suppurativa. J Clin Med 2021,10(22),5320","journal-title":"J Clin Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ced.13370","volume":"43","author":"Awad S.M.","year":"2018","unstructured":"Awad S.M.; Attallah D.A.; Salama R.H.; Mahran A.M.; Abu El-Hamed E.; Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis. Clin Exp Dermatol 2018,43(3),262-267","journal-title":"Clin Exp Dermatol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.3390\/ijms24076602","volume":"24","author":"Oris C.","year":"2023","unstructured":"Oris C.; Kahouadji S.; Durif J.; Bouvier D.; Sapin V.; S100B, actor and biomarker of mild traumatic brain injury. Int J Mol Sci 2023,24(7),6602","journal-title":"Int J Mol Sci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/14737159.2018.1428089","volume":"18","author":"Wang K.K.","year":"2018","unstructured":"Wang K.K.; Yang Z.; Zhu T.; Shi Y.; Rubenstein R.; Tyndall J.A.; Manley G.T.; An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn 2018,18(2),165-180","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jnc.14574","volume":"148","author":"Michetti F.","year":"2019","unstructured":"Michetti F.; D\u2019Ambrosi N.; Toesca A.; Puglisi M.A.; Serrano A.; Marchese E.; Corvino V.; Geloso M.C.; The S100B story: from biomarker to active factor in neural injury. J Neurochem 2019,148(2),168-187","journal-title":"J Neurochem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/18756190MTA44NjEs3","volume":"19","author":"Langeh U.","year":"2021","unstructured":"Langeh U.; Singh S.; Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders. Curr Neuropharmacol 2021,19(2),265-277","journal-title":"Curr Neuropharmacol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fnagi.2020.00156","volume":"12","author":"Papu\u0107 E.","year":"2020","unstructured":"Papu\u0107 E.; Rejdak K.; Increased cerebrospinal fluid S100B and NSE reflect neuronal and glial damage in parkinson\u2019s disease. Front Aging Neurosci 2020,12,156","journal-title":"Front Aging Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12624","volume":"281","author":"Dinarello C.A.","year":"2018","unstructured":"Dinarello C.A.; Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity. Immunol Rev 2018,281(1),5-7","journal-title":"Immunol Rev"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fimmu.2016.00604","volume":"7","author":"Luo Y.","year":"2016","unstructured":"Luo Y.; Zheng S.G.; Hall of fame among pro-inflammatory cytokines: Interleukin-6 gene and its transcriptional regulation mechanisms. Front Immunol 2016,7(DEC),604","journal-title":"Front Immunol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"E3246","DOI":"10.1073\/pnas.1421463112","volume":"112","author":"Gao Y.","year":"2015","unstructured":"Gao Y.; Tang J.; Chen W.; Li Q.; Nie J.; Lin F.; Wu Q.; Chen Z.; Gao Z.; Fan H.; Tsun A.; Shen J.; Chen G.; Liu Z.; Lou Z.; Olsen N.J.; Zheng S.G.; Li B.; Inflammation negatively regulates FOXP3 and regulatory T-cell function via DBC1. Proc Natl Acad Sci 2015,112(25),E3246-E3254","journal-title":"Proc Natl Acad Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jmcb\/mjs065","volume":"5","author":"Tan Z.","year":"2013","unstructured":"Tan Z.; Jiang R.; Wang X.; Wang Y.; Lu L.; Liu Q.; Zheng S.G.; Sun B.; Ryffel B.; ROR\u03b3t+IL-17+ neutrophils play a critical role in hepatic ischemia\u2013reperfusion injury. J Mol Cell Biol 2013,5(2),143-146","journal-title":"J Mol Cell Biol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"E3432","DOI":"10.1073\/pnas.1408780111","volume":"111","author":"Lu L.","year":"2014","unstructured":"Lu L.; Lan Q.; Li Z.; Zhou X.; Gu J.; Li Q.; Wang J.; Chen M.; Liu Y.; Shen Y.; Brand D.D.; Ryffel B.; Horwitz D.A.; Quismorio F.P.; Liu Z.; Li B.; Olsen N.J.; Zheng S.G.; Critical role of all - trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci 2014,111(33),E3432-E3440","journal-title":"Proc Natl Acad Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/biom9080345","volume":"9","author":"Xie L.","year":"2019","unstructured":"Xie L.; Huang Z.; Li H.; Liu X.; Zheng S.; Su W.; IL-38: A new player in inflammatory autoimmune disorders. Biomolecules 2019,9(8),345","journal-title":"Biomolecules"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"13677","DOI":"10.1074\/jbc.M400117200","volume":"279","author":"Towne J.E.","year":"2004","unstructured":"Towne J.E.; Garka K.E.; Renshaw B.R.; Virca G.D.; Sims J.E.; Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004,279(14),13677-13688","journal-title":"J Biol Chem"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ni1110-973","volume":"11","author":"Dinarello C.","year":"2010","unstructured":"Dinarello C.; Arend W.; Sims J.; Smith D.; Blumberg H.; O\u2019Neill L.; Goldbach-Mansky R.; Pizarro T.; Hoffman H.; Bufler P.; Nold M.; Ghezzi P.; Mantovani A.; Garlanda C.; Boraschi D.; Rubartelli A.; Netea M.; van der Meer J.; Joosten L.; Mandrup-Poulsen T.; Donath M.; Lewis E.; Pfeilschifter J.; Martin M.; Kracht M.; Muehl H.; Novick D.; Lukic M.; Conti B.; Solinger A.; Kelk P.; van de Veerdonk F.; Gabel C.; IL-1 family nomenclature. Nat Immunol 2010,11(11),973","journal-title":"Nat Immunol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-76864-y","volume":"10","author":"Watanabe S","year":"2020","unstructured":"Watanabe S; Iwata Y; Fukushima H; Saito K; Tanaka Y; Hasegawa Y; Neutrophil extracellular traps are induced in a psoriasis model of interleukin-36 receptor antagonist-deficient mice. Sci Reports 2020,10(1),1-11","journal-title":"Sci Reports"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jtos.2021.08.012","volume":"22","author":"Li J.M.","year":"2021","unstructured":"Li J.M.; Lu R.; Zhang Y.; Lin J.; Hua X.; Pflugfelder S.C.; Li D.Q.; IL-36\u03b1\/IL-36RA\/IL-38 signaling mediates inflammation and barrier disruption in human corneal epithelial cells under hyperosmotic stress. Ocul Surf 2021,22,163-171","journal-title":"Ocul Surf"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1172\/JCI63451","volume":"122","author":"Tortola L.","year":"2012","unstructured":"Tortola L.; Rosenwald E.; Abel B.; Blumberg H.; Sch\u00e4fer M.; Coyle A.J.; Renauld J.C.; Werner S.; Kisielow J.; Kopf M.; Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012,122(11),3965-3976","journal-title":"J Clin Invest"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","volume":"9","author":"Mercurio L.","year":"2018","unstructured":"Mercurio L.; Morelli M.; Scarponi C.; Eisenmesser E.Z.; Doti N.; Pagnanelli G.; Gubinelli E.; Mazzanti C.; Cavani A.; Ruvo M.; Dinarello C.A.; Albanesi C.; Madonna S.; IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis 2018,9(11),1104","journal-title":"Cell Death Dis"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"41684","DOI":"10.1074\/jbc.M112.385443","volume":"287","author":"Bachmann M.","year":"2012","unstructured":"Bachmann M.; Scheiermann P.; H\u00e4rdle L.; Pfeilschifter J.; M\u00fchl H.; IL-36\u03b3\/IL-1F9, an innate T-bet target in myeloid cells. J Biol Chem 2012,287(50),41684-41696","journal-title":"J Biol Chem"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.1121534109","volume":"109","author":"van de Veerdonk F.L.","year":"2012","unstructured":"van de Veerdonk F.L.; Stoeckman A.K.; Wu G.; Boeckermann A.N.; Azam T.; Netea M.G.; Joosten L.A.B.; van der Meer J.W.M.; Hao R.; Kalabokis V.; Dinarello C.A.; IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci 2012,109(8),3001-3005","journal-title":"Proc Natl Acad Sci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"894002","DOI":"10.3389\/fimmu.2022.894002","volume":"13","author":"Li Z.","year":"2022","unstructured":"Li Z.; Ding Y.; Peng Y.; Yu J.; Pan C.; Cai Y.; Dong Q.; Zhong Y.; Zhu R.; Yu K.; Zeng Q.; Effects of IL-38 on macrophages and myocardial ischemic injury. Front Immunol 2022,13,894002","journal-title":"Front Immunol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/039463201302600103","volume":"26","author":"Shaik Y.","year":"2013","unstructured":"Shaik Y.; Sabatino G.; Maccauro G.; Varvara G.; Murmura G.; Saggini A.; Rosati M.; Conti F.; Cianchetti E.; Caraffa A.; Antinolfi P.; Pandolfi F.; Potalivo G.; Galzio R.; Conti P.; Theoharides T.C.; IL-36 receptor antagonist with special emphasis on IL-38. Int J Immunopathol Pharmacol 2013,26(1),27-36","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"155824","DOI":"10.1016\/j.cyto.2022.155824","volume":"152","author":"de Graaf D.M.","year":"2022","unstructured":"de Graaf D.M.; Teufel L.U.; Joosten L.A.B.; Dinarello C.A.; Interleukin-38 in health and disease. Cytokine 2022,152,155824","journal-title":"Cytokine"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cei.12761","volume":"184","author":"Boutet M-A.","year":"2016","unstructured":"Boutet M-A.; Bart G.; Penhoat M.; Amiaud J.; Brulin B.; Charrier C.; Morel F.; Lecron J-C.; Rolli-Derkinderen M.; Bourreille A.; Vigne S.; Gabay C.; Palmer G.; Le Goff B.; Blanchard F.; Distinct expression of interleukin (IL)-36 \u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn\u2019s disease. Clin Exp Immunol 2016,184(2),159-173","journal-title":"Clin Exp Immunol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/iovs.62.15.31","volume":"62","author":"Li H.","year":"2021","unstructured":"Li H.; Zhu L.; Wang R.; Xie L.; Chen Y.; Duan R.; Liu X.; Huang Z.; Chen B.; Li Z.; Wang X.; Su W.; Therapeutic effect of IL-38 on experimental autoimmune uveitis: Reprogrammed immune cell landscape and reduced Th17 cell pathogenicity. Invest Ophthalmol Vis Sci 2021,62(15),31","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/ijms20061257","volume":"20","author":"Boutet M.A.","year":"2019","unstructured":"Boutet M.A.; Nerviani A.; Pitzalis C.; IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: A comprehensive review of their therapeutic potential. Int J Mol Sci 2019,20(6),1257","journal-title":"Int J Mol Sci"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"e0194667","DOI":"10.1371\/journal.pone.0194667","volume":"13","author":"Palomo J.","year":"2018","unstructured":"Palomo J.; Troccaz S.; Talabot-Ayer D.; Rodriguez E.; Palmer G.; The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression. PLoS One 2018,13(3),e0194667","journal-title":"PLoS One"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3389\/fimmu.2018.01462","volume":"9","author":"Xu W.D.","year":"2018","unstructured":"Xu W.D.; Huang A.F.; Role of interleukin-38 in chronic inflammatory diseases: A comprehensive review. Front Immunol 2018,9(JUN),1462","journal-title":"Front Immunol"},{"key":"ref=140","unstructured":"Definition of autophagy - NCI Dictionary of Cancer Terms - NCI Available form: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/autophagy (Cited 2023 Jul 27)."},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"603710","DOI":"10.3389\/fncel.2020.603710","volume":"14","author":"Misrielal C.","year":"2020","unstructured":"Misrielal C.; Mauthe M.; Reggiori F.; Eggen B.J.L.; Autophagy in multiple sclerosis: Two sides of the same coin. Front Cell Neurosci 2020,14,603710","journal-title":"Front Cell Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cmet.2019.03.003","volume":"29","author":"Lahiri V.","year":"2019","unstructured":"Lahiri V.; Hawkins W.D.; Klionsky D.J.; Watch What You (Self-) Eat: Autophagic mechanisms that modulate metabolism. Cell Metab 2019,29(4),803-826","journal-title":"Cell Metab"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"Mizushima N.","year":"2011","unstructured":"Mizushima N.; Komatsu M.; Autophagy: Renovation of cells and tissues. Cell 2011,147(4),728-741","journal-title":"Cell"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3389\/fimmu.2018.02334","volume":"9","author":"Ye X.","year":"2018","unstructured":"Ye X.; Zhou X.J.; Zhang H.; Exploring the role of autophagy-related gene 5 (ATG5) yields important insights into autophagy in autoimmune\/autoinflammatory diseases. Front Immunol 2018,9(OCT),2334","journal-title":"Front Immunol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1080\/15548627.2015.1107692","volume":"11","author":"Yao Z.","year":"2015","unstructured":"Yao Z.; Delorme-Axford E.; Backues S.K.; Klionsky D.J.; Atg41\/Icy2 regulates autophagosome formation. Autophagy 2015,11(12),2288-2299","journal-title":"Autophagy"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1007\/s00018-015-2034-8","volume":"72","author":"Wesselborg S.","year":"2015","unstructured":"Wesselborg S.; Stork B.; Autophagy signal transduction by ATG proteins: from hierarchies to networks. Cell Mol Life Sci 2015,72(24),4721-4757","journal-title":"Cell Mol Life Sci"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4161\/auto.5.2.7348","volume":"5","author":"Alirezaei M.","year":"2009","unstructured":"Alirezaei M.; Fox H.S.; Flynn C.T.; Moore C.S.; Hebb A.L.O.; Frausto R.F.; Bhan V.; Kiosses W.B.; Whitton J.L.; Robertson G.S.; Crocker S.J.; Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy 2009,5(2),152-158","journal-title":"Autophagy"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cell.2006.12.044","volume":"128","author":"Qu X.","year":"2007","unstructured":"Qu X.; Zou Z.; Sun Q.; Luby-Phelps K.; Cheng P.; Hogan R.N.; Gilpin C.; Levine B.; Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell 2007,128(5),931-946","journal-title":"Cell"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1096\/fj.11-194175","volume":"26","author":"Pierdominici M.","year":"2012","unstructured":"Pierdominici M.; Vomero M.; Barbati C.; Colasanti T.; Maselli A.; Vacirca D.; Giovannetti A.; Malorni W.; Ortona E.; Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. FASEB J 2012,26(4),1400-1412","journal-title":"FASEB J"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature09782","volume":"469","author":"Levine B.","year":"2011","unstructured":"Levine B.; Mizushima N.; Virgin H.W.; Autophagy in immunity and inflammation. Nature 2011,469(7330),323-335","journal-title":"Nature"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","volume":"176","author":"Levine B.","year":"2019","unstructured":"Levine B.; Kroemer G.; Biological functions of autophagy genes: A disease perspective. Cell 2019,176(1-2),11-42","journal-title":"Cell"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2017.01.007","volume":"176","author":"Wu D.J.","year":"2017","unstructured":"Wu D.J.; Adamopoulos i.e.; Autophagy and autoimmunity. Clin Immunol 2017,176,55-62","journal-title":"Clin Immunol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/cei\/uxac017","volume":"209","author":"Shen D.","year":"2022","unstructured":"Shen D.; Liu K.; Wang H.; Wang H.; Autophagy modulation in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2022,209(2),140-150","journal-title":"Clin Exp Immunol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"809806","DOI":"10.3389\/fimmu.2021.809806","volume":"12","author":"Zhao J.","year":"2021","unstructured":"Zhao J.; Jiang P.; Guo S.; Schrodi S.J.; He D.; Apoptosis, autophagy, NETosis, necroptosis, and pyroptosis mediated programmed cell death as targets for innovative therapy in rheumatoid arthritis. Front Immunol 2021,12,809806","journal-title":"Front Immunol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/annrheumdis-2018-213181","volume":"78","author":"Frangou E.","year":"2019","unstructured":"Frangou E.; Chrysanthopoulou A.; Mitsios A.; Kambas K.; Arelaki S.; Angelidou I.; Arampatzioglou A.; Gakiopoulou H.; Bertsias G.K.; Verginis P.; Ritis K.; Boumpas D.T.; REDD1\/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann Rheum Dis 2019,78(2),238-248","journal-title":"Ann Rheum Dis"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajhg.2013.12.002","volume":"94","author":"Mayes M.D.","year":"2014","unstructured":"Mayes M.D.; Bossini-Castillo L.; Gorlova O.; Martin J.E.; Zhou X.; Chen W.V.; Assassi S.; Ying J.; Tan F.K.; Arnett F.C.; Reveille J.D.; Guerra S.; Teruel M.; Carmona F.D.; Gregersen P.K.; Lee A.T.; L\u00f3pez-Isac E.; Ochoa E.; Carreira P.; Sime\u00f3n C.P.; Castellv\u00ed I.; Gonz\u00e1lez-Gay M.\u00c1.; Zhernakova A.; Padyukov L.; Alarc\u00f3n-Riquelme M.; Wijmenga C.; Brown M.; Beretta L.; Riemekasten G.; Witte T.; Hunzelmann N.; Kreuter A.; Distler J.H.W.; Voskuyl A.E.; Schuerwegh A.J.; Hesselstrand R.; Nordin A.; Air\u00f3 P.; Lunardi C.; Shiels P.; van Laar J.M.; Herrick A.; Worthington J.; Denton C.; Wigley F.M.; Hummers L.K.; Varga J.; Hinchcliff M.E.; Baron M.; Hudson M.; Pope J.E.; Furst D.E.; Khanna D.; Phillips K.; Schiopu E.; Segal B.M.; Molitor J.A.; Silver R.M.; Steen V.D.; Simms R.W.; Lafyatis R.A.; Fessler B.J.; Frech T.M.; AlKassab F.; Docherty P.; Kaminska E.; Khalidi N.; Jones H.N.; Markland J.; Robinson D.; Broen J.; Radstake T.R.D.J.; Fonseca C.; Koeleman B.P.; Martin J.; Ortego-Centeno N.; R\u00edos R.; Callejas J.L.; Navarrete N.; Garc\u00eda Portales R.; Camps M.T.; Fern\u00e1ndez-Nebro A.; Gonz\u00e1lez-Escribano M.F.; S\u00e1nchez-Rom\u00e1n J.; Garc\u00eda-Hern\u00e1ndez F.J.; Castillo M.J.; Aguirre M.\u00c1.; G\u00f3mez-Gracia I.; Fern\u00e1ndez-Guti\u00e9rrez B.; Rodr\u00edguez-Rodr\u00edguez L.; Vicente E.; Andreu J.L.; Fern\u00e1ndez de Castro M.; Garc\u00eda de la Pe\u00f1a P.; L\u00f3pez-Longo F.J.; Mart\u00ednez L.; Fonollosa V.; Espinosa G.; Tolosa C.; Pros A.; Rodr\u00edguez Carballeira M.; Narv\u00e1ez F.J.; Rubio Rivas M.; Ortiz Santamar\u00eda V.; D\u00edaz B.; Trapiella L.; Freire M.C.; Sousa A.; Egurbide M.V.; Fanlo Mateo P.; S\u00e1ez-Comet L.; D\u00edaz F.; Hern\u00e1ndez V.; Beltr\u00e1n E.; Rom\u00e1n-Ivorra J.A.; Grau E.; Alegre Sancho J.J.; Blanco Garc\u00eda F.J.; Oreiro N.; Fern\u00e1ndez Sueiro L.; Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet 2014,94(1),47-61","journal-title":"Am J Hum Genet"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"12050","DOI":"10.1038\/ncomms12050","volume":"7","author":"Mitchell J.S.","year":"2016","unstructured":"Mitchell J.S.; Li N.; Weinhold N.; F\u00f6rsti A.; Ali M.; van Duin M.; Thorleifsson G.; Johnson D.C.; Chen B.; Halvarsson B.M.; Gudbjartsson D.F.; Kuiper R.; Stephens O.W.; Bertsch U.; Broderick P.; Campo C.; Einsele H.; Gregory W.A.; Gullberg U.; Henrion M.; Hillengass J.; Hoffmann P.; Jackson G.H.; Johnsson E.; J\u00f6ud M.; Kristinsson S.Y.; Lenhoff S.; Lenive O.; Mellqvist U.H.; Migliorini G.; Nahi H.; Nelander S.; Nickel J.; N\u00f6then M.M.; Rafnar T.; Ross F.M.; da Silva Filho M.I.; Swaminathan B.; Thomsen H.; Turesson I.; Vangsted A.; Vogel U.; Waage A.; Walker B.A.; Wihlborg A.K.; Broyl A.; Davies F.E.; Thorsteinsdottir U.; Langer C.; Hansson M.; Kaiser M.; Sonneveld P.; Stefansson K.; Morgan G.J.; Goldschmidt H.; Hemminki K.; Nilsson B.; Houlston R.S.; Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun 2016,7(1),12050","journal-title":"Nat Commun"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/15548627.2020.1725381","volume":"17","author":"Wang Z.","year":"2021","unstructured":"Wang Z.; Zhou H.; Zheng H.; Zhou X.; Shen G.; Teng X.; Liu X.; Zhang J.; Wei X.; Hu Z.; Zeng F.; Hu Y.; Hu J.; Wang X.; Chen S.; Cheng J.; Zhang C.; Gui Y.; Zou S.; Hao Y.; Zhao Q.; Wu W.; Zhou Y.; Cui K.; Huang N.; Wei Y.; Li W.; Li J.; Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation. Autophagy 2021,17(2),529-552","journal-title":"Autophagy"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"e11278","DOI":"10.7717\/peerj.11278","volume":"9","author":"Zhang Q.","year":"2021","unstructured":"Zhang Q.; Shi H.; Zhang J.; Jiang C.; Zhou C.; The paeonol target gene autophagy-related 5 has a potential therapeutic value in psoriasis treatment. PeerJ 2021,9,e11278","journal-title":"PeerJ"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"844756","DOI":"10.3389\/fphar.2022.844756","volume":"13","author":"Klapan K.","year":"2022","unstructured":"Klapan K.; Simon D.; Karaulov A.; Gomzikova M.; Rizvanov A.; Yousefi S.; Simon H.U.; Autophagy and skin diseases. Front Pharmacol 2022,13,844756","journal-title":"Front Pharmacol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3390\/biomedicines10081817","volume":"10","author":"Kim H.J.","year":"2022","unstructured":"Kim H.J.; Park J.; Kim S.K.; Park H.; Kim J.E.; Lee S.; Autophagy: Guardian of skin barrier. Biomedicines 2022,10(8),1817","journal-title":"Biomedicines"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s13277-010-0069-x","volume":"31","author":"Chechlinska M.","year":"2010","unstructured":"Chechlinska M.; Kowalewska M.; Brzoska-Wojtowicz E.; Radziszewski J.; Ptaszynski K.; Rys J.; Kaminska J.; Nowak R.; Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma. Tumour Biol 2010,31(6),559-567","journal-title":"Tumour Biol"},{"key":"ref=163","first-page":"50","volume":"14","author":"Ghonemy S.","year":"2021","unstructured":"Ghonemy S.; Mohamed B.; Elkashishy K.; Ibrahim A.M.; Squamous cell carcinoma antigen in psoriasis: An immunohistochemical study. J Clin Aesthet Dermatol 2021,14(9),50-53","journal-title":"J Clin Aesthet Dermatol"},{"journal-title":"Tongue Cancer","author":"Gonzalez M.","key":"ref=164","unstructured":"Gonzalez M.; March A.R.; Tongue Cancer"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semcdb.2016.09.005","volume":"62","author":"Sun Y.","year":"2017","unstructured":"Sun Y.; Sheshadri N.; Zong W.X.; SERPINB3 and B4: From biochemistry to biology. Semin Cell Dev Biol 2017,62,170-177","journal-title":"Semin Cell Dev Biol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1073\/pnas.92.8.3147","volume":"92","author":"Schneider S.S.","year":"1995","unstructured":"Schneider S.S.; Schick C.; Fish K.E.; Miller E.; Pena J.C.; Treter S.D.; Hui S.M.; Silverman G.A.; A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci 1995,92(8),3147-3151","journal-title":"Proc Natl Acad Sci"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.rmed.2012.11.003","volume":"107","author":"Karaaslan C.","year":"2013","unstructured":"Karaaslan C.; Birben E.; Keskin O.; Sahiner U.; Sackesen C.; Kalayci O.; The role of SCCA1 in asthma related physiological events in the airway epithelium and the effect of promoter variants on asthma and gene function. Respir Med 2013,107(3),368-379","journal-title":"Respir Med"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/ijms19041102","volume":"19","author":"Izuhara K.","year":"2018","unstructured":"Izuhara K.; Yamaguchi Y.; Ohta S.; Nunomura S.; Nanri Y.; Azuma Y.; Nomura N.; Noguchi Y.; Aihara M.; Squamous cell carcinoma antigen 2 (SCCA2, SERPINB4): An emerging biomarker for skin inflammatory diseases. Int J Mol Sci 2018,19(4),1102","journal-title":"Int J Mol Sci"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/bjd.14426","volume":"174","author":"Watanabe Y.","year":"2016","unstructured":"Watanabe Y.; Yamaguchi Y.; Komitsu N.; Ohta S.; Azuma Y.; Izuhara K.; Aihara M.; Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: Associations with disease severity and response to the treatment. Br J Dermatol 2016,174(6),1327-1336","journal-title":"Br J Dermatol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1046\/j.0022-202x.2001.01610.x","volume":"118","author":"Takeda A.","year":"2002","unstructured":"Takeda A.; Higuchi D.; Takahashi T.; Ogo M.; Baciu P.; Goetinck P.F.; Hibino T.; Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. J Invest Dermatol 2002,118(1),147-154","journal-title":"J Invest Dermatol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/jid.2008.71","volume":"128","author":"El-Rachkidy R.G.","year":"2008","unstructured":"El-Rachkidy R.G.; Young H.S.; Griffiths C.E.M.; Camp R.D.R.; Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. J Invest Dermatol 2008,128(9),2219-2224","journal-title":"J Invest Dermatol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/jid.2010.36","volume":"130","author":"Gudjonsson J.E.","year":"2010","unstructured":"Gudjonsson J.E.; Ding J.; Johnston A.; Tejasvi T.; Guzman A.M.; Nair R.P.; Voorhees J.J.; Abecasis G.R.; Elder J.T.; Assessment of the psoriatic transcriptome in a large sample: Additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010,130(7),1829-1840","journal-title":"J Invest Dermatol"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/dj10040070","volume":"10","author":"Karmeli\u0107 I","year":"2022","unstructured":"Karmeli\u0107 I; Salari\u0107 I; Ba\u017edari\u0107 K; Salivary Scca1, Scca2 and Trop2 in oral cancer patients-a cross-sectional pilot study. Dent J 2022,10,4","journal-title":"Dent J"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pathophys.2017.09.004","volume":"25","author":"Okoye J.O.","year":"2018","unstructured":"Okoye J.O.; Erinle C.; Ngokere A.A.; Jimoh A.; Low CD4 cells and viral co-infection increase the risk of VaIN: Use of SCCA1 and Ki67 as diagno-prognostic biomarkers. Pathophysiology 2018,25(1),51-56","journal-title":"Pathophysiology"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"e0186165","DOI":"10.1371\/journal.pone.0186165","volume":"12","author":"Zhou Z.","year":"2017","unstructured":"Zhou Z.; Li W.; Zhang F.; Hu K.; The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review. PLoS One 2017,12(12),e0186165","journal-title":"PLoS One"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/diagnostics12051065","volume":"12","author":"Zhu H.","year":"2022","unstructured":"Zhu H.; Squamous cell carcinoma antigen: Clinical application and research status. Diagnostics 2022,12(5),1065","journal-title":"Diagnostics"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"1073274820983025","DOI":"10.1177\/1073274820983025","volume":"27","author":"Chen H","year":"2020","unstructured":"Chen H; Tian L; Chen J; Evaluation of 2 commercially systems for detection of serum squamous cell carcinoma antigen in pan squamous cell carcinoma. Cancer Control 2020,27(1),1073274820983025","journal-title":"Cancer Control"},{"year":"2019","key":"ref=178","unstructured":"Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients (BIOMARKER). Study Record | Beta 2019"},{"year":"2021","key":"ref=179","unstructured":"Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients 2021"},{"year":"2022","key":"ref=180","unstructured":"ATG5 as a Serum Marker of Autophagy in Psoriatic Patient 2022"},{"year":"2022","key":"ref=181","unstructured":"Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis (SCCAPSO) 2022"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501277656231128060242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/224051\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501277656231128060242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:23:39Z","timestamp":1730741019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/224051\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":181,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501277656231128060242","relation":{},"ISSN":["1389-4501"],"issn-type":[{"type":"print","value":"1389-4501"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}